Drug firm Wockhardt today reported a consolidated net loss of Rs 191.64 crore for the quarter ended March 31, 2012 burdened by exceptional items.
The company had posted a net profit of Rs 161.83 crore for the corresponding quarter previous fiscal.
Consolidated total income of the company stood at Rs 1,241.39 crore for the quarter ended March 31, 2012. It was Rs 938.73 crore for the same quarter year ago.
"The loss in the fourth quarter is due to two exceptional items. One is Rs 330 crore for goodwill write off and the other is Rs 160 crore for making provisions for corporate debt restructuring," Wockhardt Founder Chairman & Group CEO Habil Khorakiwala told PTI.
He, however, said without these exceptional items, the company's adjusted profit after tax stood at Rs 410 crore for the quarter.
Consolidated net profit of the company for the year ended March 31, 2012 stood at Rs 342.71 crore as against Rs 90.52 crore for the year ago period.
Net sales stood at Rs 4,613.80 crore for the year ended March 31, 2012. It was Rs 3,761.24 crore for the corresponding period previous fiscal.
During the year, Wockhardt USA received nine ANDA product approvals and launched six products. Overall it currently markets more than 70 products.
There were 150 global patent filings by the company, out of which 44 patents were granted, it added.
Shares of Wockhardt were today closed at Rs 717.75 on BSE, up steep 7.84% from its previous close.
